lenalidomide

P3, N=238, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Nov 2025 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Dec 2026

P2, N=79, Active, not recruiting, Alliance Foundation Trials, LLC. | Trial completion date: Jul 2026 --> Jun 2027 | Trial primary completion date: Oct 2025 --> Dec 2026

P2, N=47, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting

Immunomodulatory drugs (IMiDs) like lenalidomide and pomalidomide degrade IKZF1/3 and are combined with other therapies to treat hematologic malignancies, including multiple myeloma and non-Hodgkin lymphoma. Molecular docking studies suggested that DIX-01 may form stable ternary complexes with CRBN-IKZF1 and CRBN-GSPT1, providing a structural basis for its dual-target degradation activity. Furthermore, DIX-01 significantly inhibited tumor growth in a zebrafish xenograft model transplanted with human acute myeloid leukemia cells (MV4-11), supporting its potential as a therapeutic agent for hematologic malignancies.

Although lenalidomide/bortezomib/dexamethasone (RVd) and cyclophosphamide/bortezomib/dexamethasone (CyBorD) are clinically effective, their precise impacts on PC/B-cell maturation remain unclear. RVd responders further downregulated CD56, CD269, and CD329, and increased CD243. These shared and divergent modulations elucidate the molecular underpinnings of RVd and CyBorD efficacy and inform precision regimen selection.

P2, N=112, Completed, University of Leeds | Unknown status --> Completed | Trial completion date: Jan 2021 --> Jan 2025

P3, N=500, Not yet recruiting, PrECOG, LLC.

P2, N=150, Recruiting, Guangzhou Lupeng Pharmaceutical Company LTD. | Not yet recruiting --> Recruiting

P2, N=41, Completed, Ohio State University Comprehensive Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> May 2025 | Trial primary completion date: Aug 2025 --> May 2025

BsAbs such as epcoritamab, glofitamab, and mosunetuzumab have demonstrated substantial efficacy across both aggressive and indolent B-cell non-Hodgkin lymphomas (B-NHL), with largely manageable safety profiles...Approaches incorporating BsAbs into cytotoxic backbones and antibody-drug conjugates, as well as chemotherapy-free regimens such as BsAbs combined with lenalidomide, are discussed...BsAbs represent a major advance in B-NHL, offering high rates of deep remission with predictable safety and outpatient feasibility. As trial data continues to mature, BsAb-based regimens are poised to become foundational across multiple lines of therapy, reshaping expectations for patients with both aggressive and indolent lymphomas.

A 36-year-old woman with recurrent aphthous stomatitis had not responded to treatment with colchicine, pentoxifylline, azathioprine, dapsone or mycophenolate mofetil...A 49-year-old woman with severe recalcitrant cutaneous discoid lupus erythematosus (CDLE), systemic lupus and Raynaud phenomenon with chilblains had not responded to, had intolerance to or had adverse side-effects with multiple systemic agents including hydroxychloroquine, mepacrine, dapsone, rituximab biosimilar, mycophenolate mofetil, fumaric acid esters, acitretin, ciclosporin, thalidomide (tremor/loss of concentration), belimumab and methotrexate...Baseline and renal function monitoring is required for dose adjustment, and strict adherence to pregnancy prevention programmes is necessitated due to teratogenicity. Our three cases demonstrate lenalidomide to be a clinically beneficial, fast-acting and well-tolerated alternative off-label option for recalcitrant inflammatory dermatoses.

In patients with Richter transformation, epcoritamab monotherapy showed clinically meaningful antitumour activity, although the investigator-assessed overall response rate was below the alternative hypothesis of 50%, with a safety profile consistent with previous studies. These findings support further investigation of epcoritamab as a potential treatment option for patients with Richter transformation.